Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-05
2006-09-05
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S392000
Reexamination Certificate
active
07101887
ABSTRACT:
Disclosed are compounds of the formula:or the pharmaceutically acceptable addition salts thereof wherein:R1is halogen or C1–C4alkyl; andR2and R3are the same or different and represent hydrogen, halogen, C1–C4alkyl, C1–C4alkoxy, alkylthio, hydroxy, amino, mono(C1–C4)alkylamino, di(C1–C4)alkylamino, orR2and R3together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety,which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.
REFERENCES:
patent: 3299067 (1967-01-01), Regnier et al.
patent: 4260610 (1981-04-01), Regnier et al.
patent: 5607946 (1997-03-01), Kulagowski et al.
patent: 5859246 (1999-01-01), Thurkauf et al.
patent: 6172229 (2001-01-01), Thurkauf et al.
patent: 6426347 (2002-07-01), Thurkauf et al.
patent: 6656943 (2003-12-01), Thurkauf et al.
patent: 574271 (1993-12-01), None
patent: 211 523 (1995-06-01), None
patent: WO 93/04682 (1993-03-01), None
patent: WO 93/04684 (1993-03-01), None
patent: WO 94/06768 (1994-03-01), None
patent: WO 94/20471 (1994-09-01), None
patent: WO 97/41108 (1997-11-01), None
Reitz et al. J. med. Chem. 37 (8), p. 1060-1062 (1994).
Drug Evaluations by the American Medical Association, p. 380 (1983).
Reitz, et al., J. Med. Chem. 37, 1060-1062, 1994.
Schmidt and Martin, (1965), Toxicol. Appl. Pharmacol., 7: pp. 257-267.
Meyers, et al.,(1964), J. Org. Chem., 29: pp. 1435-1438.
Sarati, S. et al., (1991), Psychopharmacology, “Kinetics of PIREBEDIL and effects on dopamine metabolisim: hepatic biotransformation is not a determinat of its dopaminergic action in rats” 105: pp. 541-545, XP002065935.
Boyfield, L. et al., (1996), Bioorg. & Med. Chem. Lett., “N-(Substituted-Phenyl)-Piperazines: Antagonists with high Binding and Functional Selectivity for Dopamine D4 Receptors” 6:(11), pp. 1227-1232.
Reitz, A.B. et al., (1995), J. Med. Chem., “N-Aryl-N'-Benzylpiperazines as Potential Antipsychotic Agents”, 38:(21) pp. 4211-4215.
Handley, M.S., (1996), Medicinal Research Reviews, “D4 Receptors and Their Antagonists”, 16:(6) pp. 507-526.
Mach, R.H. et al., (1993), Nucl. Med. Biol., “The use of '18F14-Fluorobenzyl Iodide (FB1) in PET Radiotracer Synthesis: Model Alkylation Studies and It's Application in the Design of Dopamine D1 and D2 Receptor-based Imaging Agents”, 20:(6) pp. 777-794. XP002065565.
Prasad R. N. et al., (1968), Journal of Medicinal Chemistry, “Potential Antihypertensive Agents. II. Unsymmetrically 1,4-Disubstituted Piperazines. I” 11:(6) pp. 1144-1150. XP002036253.
Chemical Abstracts, vol. 59, No. 8732b, Morren et al.
J. Med. Chem. 1992, 35, 2369-2374, Mokrosz et al.
Morren, H. et al., “New Derivatives, N, N'-disubstituted for piperazine, with neurotropic properties”, Industrie Chimique Beige- No. 2-1963, 123-134. (with translation).
Chen Xi
Thurkauf Andrew
Bernhardt Emily
McDonnell Boehnen & Hulbert & Berghoff LLP
Neurogen Corporation
LandOfFree
1-phenyl-4-benzylpiperazines dopamine receptor subtype... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-phenyl-4-benzylpiperazines dopamine receptor subtype..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-phenyl-4-benzylpiperazines dopamine receptor subtype... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3577860